Cumulative incidence of second cancers after hematopoietic-cell transplantation (HCT).
| Second cancer . | Cumulative incidence . |
|---|---|
| Abbreviations: PTLD, post-transplant lymphoproliferative disorder; MDS, myelodysplastic syndrome | |
| Solid cancers | 1.2–1.6% at 5 years 2.2–6.1% at 10 years 3.8–14.9% at >15 years |
| PTLD | 0.6–1.4% (~75% occur within 1 year) after allogeneic HCT Rare after autologous HCT |
| MDS/leukemia | 5–15% at 5 years after autologous HCT Rare after allogeneic HCT |
| Second cancer . | Cumulative incidence . |
|---|---|
| Abbreviations: PTLD, post-transplant lymphoproliferative disorder; MDS, myelodysplastic syndrome | |
| Solid cancers | 1.2–1.6% at 5 years 2.2–6.1% at 10 years 3.8–14.9% at >15 years |
| PTLD | 0.6–1.4% (~75% occur within 1 year) after allogeneic HCT Rare after autologous HCT |
| MDS/leukemia | 5–15% at 5 years after autologous HCT Rare after allogeneic HCT |